Post operative nausea and vomiting can lead to prolonged hospital stays and readmissions in bariatric surgery patients. To compare degree of nausea and vomiting in bariatric surgical patients who received Emend in the perioperative setting to bariatric surgical patients treated in standard fashion


An observational case-control study was completed using patients in the control group from September 2017-December 2017 and patients in the treatment group from March 2018-June 2018 at our institution. The primary outcomes observed were length of stay (LOS), incidences of nausea, and incidences of emesis. The treatment group consisted of 70 bariatric surgery patients who underwent laparoscopic Roux-en-y gastric bypass (LRYGB), laparoscopic sleeve gastrectomy (SG), or revisional surgery (laparoscopic gastric band to gastric bypass, or laparoscopic sleeve gastrectomy to gastric bypass). The control group was comprised of 55 patients who underwent the above operations.


The control group had an increased number of both episodes of nausea and episodes of vomiting. There was a reduced incidence in emesis in the treatment group (p value = 0.21,not statistically significant) and nausea events/patient (not statistically significant, p value = 0.5). There were no reductions in length of stay.


Further larger studies should be considered to evaluate the trends in postoperative nausea/vomiting in bariatric patients with the use of EMEND.